In this episode, Vic speaks with Mark Durante, founder of RiseUP Medical, about the cutting-edge world of biologics and regenerative medicine. They explore how biologics like PRP, PRF, stem cells, and exosomes are being applied in areas such as neuropathy, orthopedic injuries, aesthetics, and sexual health. Mark explains the science behind cell therapies, including mesenchymal stem cells and Wharton's Jelly, and discusses RiseUP’s role in bridging labs and physicians to expand treatment options. They also review recent peer-reviewed studies focused on diabetic and chemo-induced neuropathy and discuss how regenerative treatments may complement or reduce the need for pharmaceuticals and surgery. Mark shares his personal journey from heart failure and near-disability to recovery through biologics, turning his experience into a mission to advance access and innovation in this space.

Rize UpMedical: website

Mark Durante: LinkedIn

Published Research discussed in the show:

• Exploring the Role of Mesenchymal Stem Cell–Derived Exosomes in Diabetic and Chemotherapy‐Induced Peripheral Neuropathy, Molecular Neurobiology (2024).
• Improvements in Diabetic Neuropathy with Topical Human Mesenchymal Stem Cell Conditioned Media, American Journal of Biomedical Science & Research (2024).
• Wharton’s Jelly Tissue Allograft for Connective Tissue Defects Surrounding Nerves in the Tarsal Tunnel: A Retrospective Case Series, Reports by MDPI (2024).

HF Site

YOUTUBE
INSTAGRAM
TWITTER
FACEBOOK
LINKEDIN
TIKTOK

In this episode, Vic and Marcus cover a sweeping range of major developments in healthcare, policy, and the economy. They dive deep into the UnitedHealth Group crisis, discussing the CEO resignation, DOJ investigation, and stock collapse. They analyze inflation data, Microsoft layoffs, and U.S.-China trade pauses, while also breaking down emerging trends in biotech, AI-driven drug development, hospital discharge tech, and venture capital movement. The hosts explore RFK Jr.'s impact on CMS policy, Medicaid cuts, Roundup controversies, IPO market challenges, and gene-editing breakthroughs—all framed by their signature lens on innovation, impact, and policy shifts.

Links:

6:13 - Surprise U.S.-China Trade Deal Gives Global Economy Reprieve WSJ

9:07 - Mild April Inflation Captures Early Stages of Tariff Effects WSJ

9:57 - Microsoft Slashing Thousands of Workers, Including Management Jobs WSJ

11:16 - Clarium lands $27M to fortify hospital supply chains Axios

12:09 - Olio Secures $11M to Scale Care Coordination Platform HIT

13:30 - J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus Fierce Healthcare

15:19 - Somite, a developer of foundation models for the human cell, raised $47m in Series A. X

16:35 - Cohere Health lands $90M series C round to expand AI use cases Fierce Healthcare

17:24 - Pathos AI raises $365M at $1.6B valuation Axios

18:21 - State of Private Markets: Q1 2025 Carta

23:07 - CMS proposes crackdown on 'money laundering' provider tax policies Modern Healthcare

24:25 - Drugmakers Avoid Worst-Case Pricing Scenario for Now WSJ

25:14 - Trump Leadership: If You Want Welfare and Can Work, You Must NYT-Op

28:15 - $715B Medicaid cut passes House committee in reconciliation bill Healthcare Finance

30:23 - Trump Officials Balk at RFK Jr.’s Attack on Pesticides WSJ

31:17 - CMS Innovation Center Strategy to Make America Healthy Again CMS website

36:48 - UnitedHealth CEO Is Out, Sending Shares Plummeting WSJ

40:08 - UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud WSJ

51:25 - Kaiser Permanente sees 16.1% year-over-year Q1 revenue growth following Risant acquisitions Fierce Healthcare

51:46 - Omada Health Files to Go Public: Will It Be Successful? MedCity

53:06 - Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy WSJ

53:44 - Bayer Shares Jump After Results Beat Expectations on Pharma Strength WSJ

54:10 - GSK Makes a Big Liver Disease Move With $1.2B Deal for Phase 3-Ready MASH Drug 54:10 - MedCity News

54:57 -

HF Site

YOUTUBE
INSTAGRAM
TWITTER
FACEBOOK
LINKEDIN
TIKTOK

In this episode, Vic Gatto and guest host Rick Abramson, a physician and healthcare strategist, cover the latest in AI regulation, economic indicators affecting healthcare, recent venture deals in senior living and food-as-medicine startups, and growing momentum behind the MAHA (Make America Healthy Again) movement. They discuss controversial federal appointments, shifts in FDA policy, the balance between prevention and treatment, Medicare Advantage fraud allegations, state Medicaid funding loopholes, drug manufacturing regulation, and pressures facing the nursing workforce and academic medical centers.

Previous Guest Show:

#73 - AI and Healthcare Innovation: A Conversation with Dr. Rick Abramson YouTube

Links

3:27 - U.S. nonfarm jobs grow by 177,000 in April, beating expectations UPI

4:28 - Powell rules out a preemptive rate cut to blunt any tariff impact CNBC

6:12 - U.S. and U.K. Unveil Framework for Trade Deal WSJ

7:09 - U.S. and Chinese Officials to Meet for Trade Talks WSJ

8:08 - TSOLife Secures $43M to Revolutionize Senior Living Experience HIT

10:11 - FoodHealth Company corrals $7.5M Series A to support pivot Axios

12:03 - Deerfield Management raises $600M fund in "constrained" market Axios

12:53 - Trump Picks a ‘MAHA’ Movement Leader for Surgeon General WSJ

13:38 - Biotech Stocks Fall After FDA Names Vinay Prasad To Succeed Marks at CBER BioSpace

34:31 - Justice Department Sues Big Medicare Insurers Alleging Kickbacks WSJ

36:20 - G.O.P. Targets a Medicaid Loophole Used by 49 States to Grab Federal Money NYT

41:07 - Trump orders FDA to help speed building of new drug factories Healthcare Dive

42:16 - N.I.H. Bans New Funding From U.S. Scientists to Partners Abroad NYT

44:20 - U.S. to Overhaul Curbs on AI Chip Exports After Industry Backlash WSJ

45:45 - CVS Beats Wall Street Expectations, Plans to Withdraw From ACA Business WSJ

47:22 - Clover Heath raises guidance, revenue jumps 33% Fierce Healthcare

48:29 - Vanderbilt Medical Center implements hiring freeze, layoffs amid federal funding cuts WTVF

50:33 - OHSU, Legacy Health's 10-hospital, $8B merger is no more Fierce Healthcare

52:37 - Helping nurse managers tend to their frontline workers Fierce Healthcare

53:28 - Nurse managers: The backbone of a strong nursing workforce McKinsey Report

56:38 - Virtual MSK provider IncludeHealth rebrands as LainaHealth supercharged with AI and computer vision Fierce Healthcare

57:04 - Health reports Q1 growth Axios

1:00:07 - Hims & Hers' Q1 revenue doubles to $586M, boos

HF Site

YOUTUBE
INSTAGRAM
TWITTER
FACEBOOK
LINKEDIN
TIKTOK